ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ D-ГОРМОНА (АЛЬФАКАЛЬЦИДОЛА) НА КОСТИ, МЫШЦЫ, КИШЕЧНИК И ИММУННУЮ СИСТЕМУ. Лекция

1. Abbas S., Zhang Y.H., Clohisy J.C., Abu-Amer Y. (2003). Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1-receptor. Cytokine 22:33-41.

2. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., Wong J.B. Effect of Vitamin D on Falls // JAMA 2004; 291 (16): 1999-2006.

3. Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., Thalmann B., Stahelin H.B. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500mg daily. J Am Geriatr Soc 2004;52:230-236.

4. Dukas L., Schacht E., Mazor Z., Stahelin H.B. Treatment with Alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2004. Published online.

5. Ebert-Dumig R., Jovanovic M., Kohrle J., Jakob F. (2001). Human 25(OH)vitamin D3-1-hydroxylase promoter is regulated by TNF in HepG2 and HEK-293 cell lines. Exp Clin Endocrinol Diabetes 109 (Suppl 1): S26.

6. Gallagher J.C., Fowler S.E., Detter J.R., Sherman S.S. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss // J Clin Endocrinol Metab 2001 ;86(8):3618-3628.

7. Gallagher J.C. The effects of calcitriol on falls and fractures and physical performance tests. Journal of Steroid Biochemistry & Molecular Biology 2004;89-90:497-501.

8. Godschalk M., Levy J.R., Downs Jr. R.W. (1992). Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells // J Bone Miner Res1992;7:21-27.

9. Li P., Schwarz E.M., O'Keefe R.J., Ma L., Boyce B.F., Xing L. (2004). RANK Signaling is not required for TNFl-mediated increase in CD11bhl osteoclast precursors but is essential for mature osteoclast formation in TNFa-mediated inflammatory arthritis // J Bone Miner Res 19:207-213.

10. Michel B.A., Bloch D.A., Wolfe F., Fries J.F. (1993). Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 20:1666-16669.

11. Michel B.A., Bloch D.A., Fries J.F. (1991). Predictors of fractures in early rheumatoid arthritis. J Rheumatol 18:804-808.

12. Mahonen A., Maenpaa P.H. (1994). Steroid hormone modulation of vitamin D receptor levels in human MG-63 osteosarcoma cells. Biochem Biophys Res Commun 205:1179-1186.

13. Nanes M.S. (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003;321:1-15.

14. Oelzner P., Franke S., Muller A., Hein G., Stein G. (1999). Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology 38:841-847.

15. Oelzner P., Muller A., Deschner F., Huller M., Abendroth K., Hein G., Stein G. (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193-198.

16. Scharla S.H., Minne H.W., Lempert U.G., Leidig G., Hauber M., Raedsch R., Ziegler R. (1994). Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinology 102:44-49.

17. Scott E.M., Gaywood I., Scott B.B. For the British Society of Gastroenterology (2000). Guidelines for osteoporosis in celiac disease and inflammatory bowel disease. Gut 46(Suppl1):l1-l8.

18. Shany S., Cohen-Lahav M., Chaimovitz C., Douvdevani A. (2002). Regulation of NF-kB activity leads to the down-regulation of TNFa expression caused by 1,25(OH)2D3 and 1,24(S)(OH)2D2 in inflammatory cells. In: DeLuca symposium on vitamin D, page 24.

19. Feher J.J., Wasserman R.H. (1979). Intestinal calcium-binding protein and calcium abscrption in ocrtisol-trectod ohioko. Effect of vitamine D3 and 1,25-dhydroxyvitamin D3 // Endocrinology 104;547-551.

20. Canalis E., Delany A.M. (2002). Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966:73-81.

21. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblastgs and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J clin Invest 102:274-282.

22. Weinstein R.S., Nicholas R.W., Manolagas S.C. (2000). Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907-2912.

23. Haug C.J., Aukrust P., Haug E., Morkrid L., Muller F., Froland S.S. (1998). Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis // J Clin Endocrinol Metab 83:3832-3838.

24. Minne H.W., Pfeilschifter J., Scharla S., Mutschelknauss S., Schwarz A., Krempien B., Ziegler R. (1984). Inflammation-mediated osteopenia in the rat: A new animal model for pathological loss of bone mass // Endocrinology 115:50-5410.

25. Scharla S., Schmidt-Gayk H., Sattar P. Exclusion of autonomous 1,25(OH)2vitamin D% (calcitriol) formation as a pathogenetic principle of inflammation-mediated osteopenia (IMO). Acta endocrinologica 1984; 105(Supplementum 264): 7.

26. Scharla S.H., Strong D.D., Mohan S., Baylink D.J., Linkhart Т.А. (1991). 1,25-Dihydroxyvitamin DS differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts// Endocrinology 129: 3139-3146.

27. Costa E.M., Blau H.M., Feldman D. (1986). Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells// Endocrinology 119:2214-2220.

28. DeLuca H.F., Cantorna M.T. (2001). Vitamin D. Its role and uses in immunology. FASEB J 15:2579-2585.

29. Mathieu C., Adorini L. (2002) The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. TRENDS in Molecular Medicine 8:174-179.

30. Sorensen O.H., Lund B.l., Saltin B., Lund B.J., Anderson R.B., Hyorth L., Melson F., Mosekilde L. (1979). Myopathy in bone loss of ageing: Improvement by treatment with 1a-hydroxycholecalciferol and calcium // Clinical Science 56:157-161.

31. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S (1998). Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochemical and Biophysical Research Communications 250:776-781.

32. Reginster J.Y., Kuntz D., Verdickt W., Wouters M., Guillevin L., Menkes C.J., Nielsen К. (1999). Prophylactic use of Alfacalcidol in corticosteroid-induced osteoporosis // Osteoporos Int 9:75-81.

33. Ringe J.D., Coster A., Meng T., Schacht E., Umbach R. (1999) Treatment of glucocorticoid-induced osteoporosis with Alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337-340.

34. Ringe J.D., Dorst A., Faber H., Schacht E., Rahlfs V.W. (2004). Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63-70.

35. Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. (2003). Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthritis + rheuma 23: 268-274.